



CONSTIPATION / MIXED MASTER

subj.#	subj.	initial treatment	gender	IBS type	symptom severity total		change at 4 wk	change at 8 week from baseline	
					baseline	8 weeks			
39	SK	placebo	m	C	48	46	60	-3.2%	26.3%
42	ES	placebo	m	C	84	88	81	5.4%	-3.0%
45	MS	placebo	m	C					
48	NS	placebo	m	C					
51	YT	placebo	m	C	55	62	62	13.8%	13.8%
53	MB	placebo	m	C	48	48	51	0.0%	6.3%
54	EA	placebo	m	m	45	39	38	-12.4%	-14.6%
62	UC	placebo	m	m	62	51	53	-17.1%	-13.8%
76	EW	placebo	m	m	84	71	75	-15.5%	-10.7%
79	PB	placebo	m	m	59	45	46	-23.1%	-21.4%
83	PA	placebo	m	C	59	58	66	-0.9%	12.8%
49	YV	placebo	f	C	67	64	64	-4.5%	-4.5%
55	TB	placebo	f	m	81.5	63	71	-22.7%	-12.9%
61	AC	placebo	f	C	50.5	47	44	-6.9%	-12.9%
63	JK	placebo	f	m	46	61	66	32.6%	43.5%
68	SB	placebo	f	C	70	39	39	-44.3%	-44.3%
82	SA	placebo	f	C					
86	CG	placebo	f	C	60	54	52	-10.0%	-13.3%
89	NR	placebo	f	C	79.5	77	75	-3.1%	-5.7%
40	SK	active Tx	m	m	63	47	47	-25.4%	-25.4%
44	IC	active Tx	m	m	61.5	38	42	-38.2%	-31.7%
67	ZF	active Tx	m	C	52.5	52	42	-1.0%	-20.0%
72	YB	active Tx	m	m	43	30	34	-30.2%	-20.9%
73	MH	active Tx	m	C	94	25	27	-73.4%	-71.3%
75	YC	active Tx	m	m					
91	PR	active Tx	m	C	62.5	48	48	-23.2%	-23.2%
94	DS	active Tx	m	C	52.5	38	35	-27.6%	-33.3%
43	LL	active Tx	f	m					
52	GR	active Tx	f	m					
56	ET	active Tx	f	m	53	59	57	11.3%	7.5%
71	MS	active Tx	f	m	42.5	26	46	-38.8%	8.2%
95	PH	active Tx	f	C					



CONSTIPATION / MIXED 4 WEEKS

Symptom Severity Total - Placebo						
seria l#	subj init.	genc	type	base line	4 wks	change at 4 wk
1	SK	m	C	48	46	-3.2%
2	ES	m	C	84	88	5.4%
3	YV	f	C	67	64	-4.5%
4	YT	m	C	55	62	13.8%
5	MB	m	C	48	48	0.0%
6	EA	m	Mx	45	39	-12.4%
7	TB	f	Mx	81.5	63	-22.7%
8	AC	f	C	50.5	47	-6.9%
9	UC	m	Mx	62	51	-17.1%
10	JK	f	Mx	46	61	32.6%
11	SB	f	C	70	39	-44.3%
12	EW	m	Mx	84	71	-15.5%
13	PB	m	Mx	59	45	-23.1%
14	PA	m	C	59	58	-0.9%
15	CG	f	C	60	54	-10.0%
16	NR	f	C	79.5	77	-3.1%
Average reduction at week 4 (Placebo)						-7.0%

Symptom Severity Total - Active Tx						
serial #	subj. init.	gender	type	base line	4 wks	change at 4 wk
1	SK	m	Mx	63	47	-25.4%
2	IC	m	Mx	61.5	38	-38.2%
3	ET	f	Mx	53	59	11.3%
4	ZF	m	C	52.5	52	-1.0%
5	MS	f	Mx	42.5	26	-38.8%
6	YB	m	Mx	43	30	-30.2%
7	MH	m	C	94	25	-73.4%
8	PR	m	C	62.5	48	-23.2%
9	DS	m	C	52.5	38	-27.6%
Average reduction at week 4 (Active Treatment)						-27.4%

	Treatment	N	Mean	Std. Deviation
% Change in Total Severity Score from baseline to week 4	PLACEBO	16	7.0	17.1
	TREATMENT	9	27.4	24.0

		t-test for Equality of Means	
		Sig. (2-tailed)	Mean Difference
% Change in Total Severity Score from baseline to week 4	Equal variances assumed	.02	-20.40

CONSTIPATION / MIXED 8 WEEKS

Symptom Severity Total - Placebo						
seria l#	subj init.	gender	type	base line	8 wks	change at 8 week from baseline
1	SK	m	C	48	60	26.3%
2	ES	m	C	84	81	-3.0%
3	YV	f	C	67	64	-4.5%
4	YT	m	C	55	62	13.8%
5	MB	m	C	48	51	6.3%
6	EA	m	Mx	45	38	-14.6%
7	TB	f	Mx	81.5	71	-12.9%
8	AC	f	C	50.5	44	-12.9%
9	UC	m	Mx	62	53	-13.8%
10	JK	f	Mx	46	66	43.5%
11	SB	f	C	70	39	-44.3%
12	EW	m	Mx	84	75	-10.7%
13	PB	m	Mx	59	46	-21.4%
14	PA	m	C	59	66	12.8%
15	CG	f	C	60	52	-13.3%
16	NR	f	C	79.5	75	-5.7%
Average reduction at week 8 (Placebo)						-3.4%

Symptom Severity Total - Active Tx						
serial #	subj. init.	gender	type	base line	8 wks	change at 8 week from baseline
1	SK	m	Mx	63	47	-25.4%
2	IC	m	Mx	61.5	42	-31.7%
3	ET	f	Mx	53	57	7.5%
4	ZF	m	C	52.5	42	-20.0%
5	MS	f	Mx	42.5	46	8.2%
6	YB	m	Mx	43	34	-20.9%
7	MH	m	C	94	27	-71.3%
8	PR	m	C	62.5	48	-23.2%
9	DS	m	C	52.5	35	-33.3%
Average reduction at week 8 (Active Treatment)						-23.3%

	Treatment	N	Mean	Std. Deviation
% Change in Total Severity Score from baseline to week 8	PLACEBO	16	3.4	20.5
	TREATMENT	9	23.3	23.6

		t-test for Equality of Means	
		Sig. (2-tailed)	Mean Difference
% Change in Total Severity Score from baseline to week 8	Equal variances assumed	.04	-19.94